




GreenLight XPS™

Laser Therapy System

Drive lasting symptom relief for benign prostatic hyperplasia (BPH)



Accelerate patient recovery with GreenLight Laser Therapy¹

A proven treatment for 20+ years and for more than 1 million patients, GreenLight delivers the lasting outcomes you and your patients seek with a low risk of serious adverse events.^{1,3}



Guidelines^{4,5}:

Recommended by the European Urology Association (EAU) as an alternative to TURP clinicians should consider photoselective vaporization of the prostate (PVP) as an option using 180W platforms for patients for treatment of lower urinary tract symptoms (LUTS) attributed to BPH (Strong Recommendation, Evidence Level: Grade 1b)

Recommended by the National Institute for Health and Care Excellence (NICE) to treat BPH in people with urinary retention, prostates up to 100 ml in volume, and a higher risk of bleeding.⁵



Proven, lasting outcomes¹

Get similar long-term durability as with transurethral resection of the prostate (TURP), with a positive safety profile.^{6,7}

Fast recovery.¹⁰ High patient satisfaction.⁸

Reduce the likelihood of serious adverse events for your patients and help them get back to life faster.³ Compared to TURP, GreenLight results in:



1.5%60-month BPH recurrence requiring surgical reintervention¹



50% less catheterization time⁸ (22 hours vs. 46.7 hours)



3.3% 60-month BPH recurrence requiring medication¹



2x faster return to stable health⁸ (26 hours vs. 52.8 hours)



84.6% complication-free rate at 1 year vs. 80.5% for TURP⁸



Similarup to 85% ejaculatory preservation rate at 6-month^{9,**}



Up to 15 years' reduction in LUTS⁶



Lower incidence of perioperative complications, including bleeding, blood transfusion, clot retention, capsule perforation, and TUR syndrome⁷

The GreenLight XPS Laser System is intended for the surgical incision, excision, vaporization, ablation, hemostasis, and coagulation of urological soft tissue. With all medical procedures, there are risks associated with the procedure and the use of the device. This risks associated with the GreenLight Laser System included but are not limited to: Painful or frequent urination, urgent need to urinate, blood in the urine or semen, urinary tract infection, inability to urinate or completely empty the bladder, scarring and narrowing of the urethra, narrowing of the bladder neck (areas of the bladder that connects to the urethra), urinary incontinence, dry orgasm, erectile dysfunction, and severe infection.



Accelerated patient recovery^{1,10,13}

Own the field of prostate treatment and optimize patient outcomes.¹ GreenLight gives you the flexibility to perform the technique you choose with nine principles of PVP, 12 principles of vaporization incision technique (VIT), antatomic vaporization, GreenLEP, and the Hood Sparing Technique^{9,12,14,15}

The 532 nm wavelength's high hemoglobin and low water absorption deliver rapid tissue vaporization and an optimized coagulative effect, so you can deliver quick symptom relief.^{1,10,13}

Boston Scientific supports you at every step with world-class training, continual technique improvements, and access to a network of fellow practitioners.





Model Number

Lasers	
GreenLight XPS™ Laser Therapy System	0010-0210S-G0
Fibers	
Angled Delivery Device, MoXy™ Fiber	0010-2400
GreenLight HPS™ Laser fiber (Compatible with GreenLight XPS™ system)	0010-2090
Protective Filters	
Video Camera Gold Filter for Rigid Endoscope 1.25" diameter	0010-0721
Video Camera Gold Filter for Rigid Endoscope .95" diameter	0010-0722
Video Camera Blue Filter for Rigid Endoscope 1.25" diameter	0010-0725
Video Camera Blue Filter for Rigid Endoscope .95" diameter	0010-0726
Video Camera Green Filter for Rigid Endoscope 1.23" diameter	0010-0728
Protective Eyewear	
Protective Glasses, Physicians	0010-0008
KTP/532 Plastic Protective Glasses (532 nm protection only)	0010-7030
Other Accessories	
GreenLight XPS Operators Manual	0010-0240
Gas Seals (pack of 12)	0010-0370



References:

- Law KW, Tholomier C, Nguyen D-D, et al. Global Greenlight Group: Largest international Greenlight experience for benign prostatic hyperplasia to assess efficacy and safety. World J Urol. 2021 Dec;39(12):4389–4395.
- 2. Corbel L, Della Negra E, Berquet G, Codet YP, Boulière F, Braguet R, Trifard F. Vaporisation laser prostatique par GreenLight (180 W) en ambulatoire: évaluation prospective sur 115 patients [Ambulatory prostate photoselective vaporisation with GreenLight laser (180W): prospective evaluation from 115 patients]. Prog Urol. 2014 Oct;24(12):733-7. French. doi: 10.1016/j.purol.2014.08.238. Epub 2014 Sep 17. PMID: 25241244.
- 3. Thomas JA, Tubaro A, Barber N, et al. A multicenter randomized noninferiority trial comparing GreenLight–XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: Two-year outcomes of the GOLIATH Study. *Eur Urol.* 2016 Jan;69(1):94–102.
- 4. EAU Guidelines. Edn. presented at the EAU Annual Congress Paris April 2024. ISBN 978-94-92671-23-3.
- 5. National Institute for Health and Care Excellence (NICE). GreenLight XPS for treating benign prostatic hyperplasia. 2022 Nov 29. nice.org.uk/guidance/mtg74/resources/greenlight-xps-for-treating-benign-prostatic-hyperplasia-pdf-64372237176517. Accessed December 12, 2022.
- 6. Ibrahim A, Touma N, AlShammari AM, et al. GreenLight laser prostatectomy: Are outcomes sustainable after a decade of surgery? A single center experience with up to 15 years' follow-up. *J Urol.* 2021 Sept 1;206(Suppl 3):e163–4.
- Lai S, Peng P, Diao T, et al. Comparison of photoselective green light laser vaporisation versus traditional transurethral resection for benign prostate hyperplasia: An updated systematic review and meta-analysis of randomised controlled trials and prospective studies. BMJ Open. 2019 Aug 21:9(8):e028855.
- 8. Bachmann A, Tubaro A, Barber N, et al. A European multicenter randomized noninferiority trial comparing 180 W GreenLight XPS laser vaporization and transurethral resection of the prostate for the treatment of benign prostatic obstruction: 12-month results of the GOLIATH study. *J Urol.* 2015 Feb:193(2):570–8.
- 9. Kini M, Te AE, Kashanian JA, et al. Ejaculatory hood-sparing photoselective vaporization of the prostate vs. bipolar button plasma vaporization of the prostate in the surgical management of benign prostatic hyperplasia. *J Endourol*. 2020 Mar;34(3):322–329.
- 10. Bachmann A, Tubaro A, Barber N, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial the GOLIATH study. Eur Urol. 2014 May;65(5):931–42
- 11. Capitán C, Blázquez C, Martin MD, et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: A randomized clinical trial with 2-year follow-up. Eur Urol. 2011 Oct;60(4):734–9.
- 12. Law KW, Elterman DS, Cash H, Rijo E, Chughtai B, Misrai V, Zorn KC. Anatomic GreenLight laser vaporization-incision technique for benign prostatic hyperplasia using the XPS LBO-180W system: How I do it. Can J Urol. 2019 Oct;26(5):9963-9972. PMID: 31629449.
- 13. Castellani D, Pirola GM, Rubilotta E, et al. GreenLight Laser™ Photovaporization versus transurethral resection of the prostate: a systematic review and meta-analysis. Res Rep Urol. 2021 May:13:263-71.
- 14. data on file Boston Scientific
- 15. Destefanis P, Sibona M, Soria F, Vercelli E, Vitiello F, Bosio A, Bisconti A, Lillaz B, Gontero P. Ejaculation-sparing versus non-ejaculation-sparing anatomic GreenLight laser enucleo-vaporization of the prostate: first comparative study. World J Urol. 2021 Sep;39(9):3455-3463. doi: 10.1007/s00345-021-03615-7. Epub 2021 Feb 16. PMID: 33591378.

*Stable health status: the time from entering recovery room until the earlier of discharge from the medical facility or the first successful voiding trial without an ongoing treatment-related adverse event.

**preliminary single centered randomized trial (n=27)



www.bostonscientific.eu

© 2025 Boston Scientific Corporation or its affiliates. All rights reserved.

C€ 0344